{"id":900364,"date":"2025-10-27T09:57:42","date_gmt":"2025-10-27T13:57:42","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/hoth-therapeutics-launches-va-backed-study-of-novel-gdnf-weight-loss-therapy-targeting-obesity-and-fatty-liver-disease\/"},"modified":"2025-10-27T09:57:42","modified_gmt":"2025-10-27T13:57:42","slug":"hoth-therapeutics-launches-va-backed-study-of-novel-gdnf-weight-loss-therapy-targeting-obesity-and-fatty-liver-disease","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/hoth-therapeutics-launches-va-backed-study-of-novel-gdnf-weight-loss-therapy-targeting-obesity-and-fatty-liver-disease\/","title":{"rendered":"Hoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy Targeting Obesity and Fatty Liver Disease"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n Collaborative program with the U.S. Department of Veterans Affairs aims to validate GDNF as a first-in-class biologic for obesity and hepatic health.<\/i>
\n <\/b>\n <\/p>\n

\n
\n NEW YORK<\/span>
\n <\/span>, Oct. 27, 2025<\/span><\/span> \/PRNewswire\/ — Hoth Therapeutics, Inc.<\/i>\u00a0(NASDAQ:\u00a0HOTH<\/b>), a biopharmaceutical company focused on developing breakthrough therapies for metabolic, dermatologic, and inflammatory diseases, today announced the initiation of a\u00a0U.S. Department of Veterans Affairs (VA)\u2013backed study<\/b>\u00a0evaluating the potential of\u00a0glial cell line\u2013derived neurotrophic factor (GDNF)<\/b>as a novel therapy for\u00a0obesity and fatty liver disease (hepatic steatosis)<\/b>.<\/p>\n

\n

\n
\n \"(PRNewsfoto\/Hoth
\n <\/a>\n <\/p>\n<\/p><\/div>\n

The program, led by\u00a0Dr. Srinivasan<\/b>\u00a0and her research team at the\u00a0Atlanta VA Medical Center<\/b>, will explore the ability of GDNF to induce weight loss and promote resolution of fatty liver disease through metabolic and neurotrophic mechanisms.\u00a0<\/p>\n

“We’re honored to work alongside the VA on this important initiative,” said\u00a0Robb Knie<\/span><\/b>, Chief Executive Officer of Hoth Therapeutics. “Metabolic disease and obesity continue to impact millions of people globally. By targeting both neural and metabolic pathways, GDNF could represent an entirely new class of biologic therapy for obesity and related liver conditions. We’re excited about the early momentum this study brings.”<\/p>\n

\n Study Timeline and Objectives<\/b>\n <\/p>\n

The program is structured under\u00a0Aim 1 of the approved Statement of Work (SOW)<\/b>, with key milestones as follows:<\/p>\n